Denali Therapeutics Inc

Stock Chart, Company Information, and Scan Results

$15.51(as of Aug 25, 2:36 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Denali Therapeutics Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$15.51
Ticker SymbolDNLI
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees486
CountyUSA
Market Cap$2,264.8M
EBIDTA-529.4M
10-Day Moving Average14.60
P/E Ratio-5.54
20-Day Moving Average14.27
Forward P/E Ratio0.00
50-Day Moving Average14.32
Earnings per Share-2.81
200-Day Moving Average17.77
Profit Margin-Infinity%
RSI61.22
Shares Outstanding146.2M
ATR0.77
52-Week High33.33
Volume2,743,924
52-Week Low10.57
Most Recent Support Level14.15
Book Value1,027.1M
Most Recent Resistance Level15.15
P/B Ratio2.59
Upper Keltner16.00
P/S RatioInfinity
Lower Keltner12.54
Debt-to-Equity Ratio16.00
Next Earnings Date10/30/2025
Cash Surplus50.2M
Next Ex-Dividend DateUnknown

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Denali Therapeutics Inc In Our Stock Scanner

As of Aug 25, 2025
example chart graphic
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.